The shares had been picked up by two home fund homes. Kotak Mahindra Mutual Fund acquired 21.02 lakh shares, whereas Aditya Birla Solar Life Mutual Fund bought 13.48 lakh shares. Each transactions had been executed on the similar value of Rs 2,968 per share.
Ajanta Pharma is a specialty pharmaceutical firm with a presence throughout branded generics, rising markets and choose developed markets. The corporate has constructed a powerful franchise in therapeutic segments reminiscent of ophthalmology, cardiology, dermatology and ache administration, whereas additionally increasing its footprint in worldwide markets.
The corporate has been one of many stronger performers within the pharmaceutical house, benefiting from regular earnings development, wholesome margins and a sturdy stability sheet. Buyers have additionally favoured the inventory because of its deal with branded formulations and comparatively restricted publicity to pricing pressures within the US generics market.
Ajanta Pharma reported good fourth quarter outcomes, with income and EBITDA coming in 1-3%, forward of analysts estimates. PAT was 23% larger than the views, helped by larger Different earnings and a decrease tax charge. US generics enterprise sustained strong development momentum, up 47% YoY in USD phrases
“We elevate our FY27E-FY28E core earnings estimates by 2%. AJP trades at 31.2x FY27E core P/E. We retain our goal value at Rs 3,115 primarily based on 29.9x FY28E core P/E plus money per share. We retain our Accumulate ranking. Geopolitical disruptions to the enterprise and a spike in uncooked supplies value & freight price are key dangers to our name. We introduce FY29 estimates,” Elara Capital stated publish the earnings.
